Concurrent cisplatin/etoposide (PE) and twice-daily thoracic radiotherapy (BID TRT) followed by weekly dose intensive regimen (CODE) with human granulocyte-colony stimulating factor (G-CSF) for limited stage (LS) small cell lung cancer (SCLC)

✍ Scribed by Inoue, A; Kubota, K; Kodama, T; Tamura, T; Ohe, Y; Kunitoh, H; Sekine, I; Nishiwaki, Y; Saijo, N

• Book ID: 118569866
• Publisher: Elsevier Science
• Year: 2000
• Tongue: English
• Weight: 117 KB
• Volume: 29
• Category: Article
• ISSN: 0169-5002
• DOI: 10.1016/s0169-5002(00)80321-9